Log In
BCIQ
Print this Print this
 

LPLchip

  Manage Alerts
Collapse Summary General Information
Company Progenika Biopharma S.A.
DescriptionComplete and partial lipoprotein lipase (LPL) deficiency diagnostic based on DNA-chip technology
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentApproved
Standard IndicationGastrointestinal, Diagnostic
Indication DetailsDiagnose complete and partial lipoprotein lipase deficiency (LPLD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/02/2009

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today